At AAAAI 2026, Robert Wood, MD, of Johns Hopkins University discusses remibrutinib, omalizumab, and OIT for treating food allergy.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved the ...

XOLAIR is given in 1 or more injections under the skin (subcutaneous), 1 time every 2 or 4 weeks. In people with asthma, CRSwNP and food allergy, a blood test for a substance called IgE must be ...

SAN DIEGO -- Omalizumab (Xolair) injections outperformed oral immunotherapy (OIT) in increasing tolerance among children with multi-food allergy, largely because many patients couldn't tolerate OIT, ...

Findings showed 67% of the omalizumab group achieved the primary endpoint compared with 7% of the placebo group. Treatment with omalizumab, an anti-IgE antibody, significantly increased the amount of ...

Please provide your email address to receive an email when new articles are posted on . Omlyclo is approved to treat the same four conditions as omalizumab. There are now three doses/solutions of ...

A new study finds that the asthma medication Xolair may substantially reduce severe allergic reactions in people who have multiple food allergies and are accidentally exposed to those foods. Data ...

Please provide your email address to receive an email when new articles are posted on . Data came from the FDA Adverse Event Reporting System from 2004 to 2024. Omalizumab had significant associations ...

The FDA approved omalizumab-igec (Omlyclo) as the first biosimilar for omalizumab (Xolair) and the first for any respiratory condition in the U.S., drugmaker Celltrion announced Monday. The ...

On December 3, 2025, Celltrion announced that the FDA has approved a new dose of OMLYCLO (omalizumab-igec), the first and only biosimilar designated as interchangeable with Genentech and Novartis’s ...

Findings showed equivalent efficacy in change from baseline in weekly itch severity score between omalizumab-igec 300mg and Xolair 300mg. The Food and Drug Administration (FDA) has approved Omlyclo ® ...

Participants in the OUtMATCH trial are allergic to peanuts and at least two other foods among milk, eggs, wheat, cashews, walnuts and hazelnuts. A clinical trial has found that the medication ...